translation agency

FDA News
Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination
Richard Klein & Yodit Belew, M.D.
August 10, 2011
Food and Drug Administration - August 10, 2011

On August 10, 2011, FDA approved Complera(TM), a fixed dose combination (FDC) drug product containing emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the treatment of HIV. The recommended dose of Complera(TM) is one tablet, containing 200mg/25mg/300mg of FTC/RPV/TDF, once daily, taken orally with a meal.